Allogeneic stem cell transplantation for mantle cell lymphoma - Final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)

Annals of Hematology

Volumn 93, Issue 9, 2014, Pages 1587-1597

  Krüger, William H ^a   Hirt, Carsten ^a   Basara, Nadezda ^b   Sayer, Herbert G ^c   Behre, Gerhard ^d   Fischer, Thomas ^e   Grobe, Norbert ^f   Maschmeyer, Georg ^g   Niederwieser, Dietger ^b   Dölken, Gottfried ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f Dietrich Bonhoeffer Hospital   (Germany)

^g Ernst von Bergmann Hospital   (Germany)

Author keywords

Allogeneic stem cell transplantation; Clinical trial; Graft versus lymphoma effect; Mantle cell lymphoma

Indexed keywords

BENDAMUSTINE; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MORPHINE; RITUXIMAB; THYMOCYTE ANTIBODY; TREOSULFAN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; DONOR LYMPHOCYTE INFUSION; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA CELL; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; NEPHROTOXICITY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REDUCED INTENSITY CONDITIONING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMATITIS;

ADULT; AGED; CLINICAL TRIALS AS TOPIC; FEMALE; GERMANY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84905575740     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2087-z     Document Type: Article

References (25)

1. Barista I, Romaguera JE, Cabanillas F (2001) Mantle-cell lymphoma. Lancet Oncol 2(3):141-148 (Pubitemid 33585925)
2. Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S et al (2001) Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 15(11):1785-1791 (Pubitemid 33061848)
3. Dreyling M, Kluin-Nelemans HC, Bea S, Hartmann E, Salaverria I, Hutter G et al (2011) Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: Report of the 10th Annual Conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma
4. Williams ME, Swerdlow SH, Meeker TC (1993) Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 7(9):1437-1440 (Pubitemid 23291087)
5. Rimokh R, Berger F, Delsol G, Digonnet I, Rouault JP, Tigaud JD et al (1994) Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 83(7):1871-1875 (Pubitemid 24107911)
6. Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D et al (2004) Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 15(2):283-290 (Pubitemid 38262629)
7. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687-2693
8. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S et al (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102(2):749-755 (Pubitemid 36842002)
9. Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T et al (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107(6):2271-2278 (Pubitemid 43345544)
10. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM et al (2009) Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 27(26):4365-4370
11. Kroger N, Hoffknecht M, Dreger P, Kruger W, Zeller W, Krull A et al (1998) Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 21(1):55-57 (Pubitemid 28043437)
12. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F et al (2002) Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99(1):75-82
13. Martinez C, Carreras E, Rovira M, Urbano-Ispizua A, Esteve J, Perales M et al (2000) Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 26(6):677-679
14. Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M et al (1999) Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 10(11):1293-1299
15. Khouri IF, Champlin RE (2004) Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 31(1):22-26 (Pubitemid 38209500)
16. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558-565
17. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6(10):1562-1568 (Pubitemid 19092391)
18. Hirt C, Schuler F, Dolken L, Schmidt CA, Dolken G (2004) Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR. Blood 104(3):904-905 (Pubitemid 38970591)
19. Schuler F, Dolken SC, Hirt C, Dolken MT, Mentel R, Gurtler LG et al (2006) No evidence for simian virus 40 DNA sequences inmalignant non-Hodgkin lymphomas. Int J Cancer 118(2):498-504 (Pubitemid 41779092)
20. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH et al (2008) Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 14(4):418-425 (Pubitemid 351372748)
21. Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K et al (2010) Outcome following reduced-intensity allogeneic stem cell transplantation (RIC alloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 16(10):1419-1427
22. Ganti AK, Bierman PJ, Lynch JC, Bociek RG, Vose JM, Armitage JO (2005) Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 16(4):618-624 (Pubitemid 40613329)
23. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A et al (2003) Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21(23):4407-4412 (Pubitemid 46621818)
24. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104(12):3535-3542 (Pubitemid 39564424)
25. Le Gouill S, Kroger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I et al (2012) Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 23(10):2695-2703